In order to provide our users with a better overall experience, we ask for more information from Facebook when using it to login so that we can learn more about our audience and provide you with the best possible experience. We do not store specific user data and the sharing of it is not required to login with Facebook.
No Verizon logo on its HTC One Max? Could this be? We wouldn't put any money on it. Especially because — and we'll spoil this here and show you again after the break — what Verizon's got on its website is different than what HTC's showing us.
Anyhoo. It's coming to Verizon — we just don't know when or for how much. (Read whatever you want into that Nov. 1 date on the home screen there.)
TUESDAY, APRIL 20, 2010, AT 6:19 PM Tornado Kills at Least Five in Oklahoma
FRIDAY, APRIL 29, 2011, AT 3:07 PM Obama Gets Firsthand Look at a Tornado Damage
TUESDAY, APRIL 20, 2010, AT 6:19 PM Tornado Kills at Least Five in Oklahoma. Very long title. Long long long. Tornado Kills at Least Five in Oklahoma. Very long title. Long long long.
TUESDAY, APRIL 20, 2010, AT 6:19 PM Tornado Kills at Least Five in Oklahoma. Very long title. Long long long. Tornado Kills at Least Five in Oklahoma. Very long title. Long long long.
The brand new Star Wars animated series Star Wars Rebels just released the very first, all new villain for the Empire. Take a gander at the Inquisitor. The Inquisitor premiered at the New York Comic-Con panel thanks to this video hosted by Dave Filoni. The Inquisitor’s job is to track down down the remaining Jedi Knights. He’s under the control of Darth Vader—HOWEVER do not think that The Inquisitor negates Order 66. Everyone at the panel said this is still something very important to them and they want to continue to place importance around the fact that Luke is the last Jedi. And finally, even though we got this character there is still no announcement on which additional characters would be returning to the animated series.
It’s unknown if any of the animated characters will appear in the live-action Star Wars films that are in production but I suspect there will be enough new characters to go around. I don’t watch the animated Star Wars shows (except for the Star Wars/Lego cartoon that I caught a few weeks ago and really loved) but I’m gonna guess that characters we see in the toons will likely appear on the big screen, too. It’s weird to think of a bunch of new Star Wars characters heading our way but Disney paid a lot of money for the franchise. They’re gonna do everything they can to make it their own.
NEW YORK (Reuters) - A former senior bank examiner at the Federal Reserve Bank of New York filed a wrongful termination lawsuit on Thursday, saying she was fired after refusing to alter a critical examination of Goldman Sachs Group Inc .
The former employee, Carmen Segarra, said that in her seven months of examining Goldman's legal and compliance divisions, she found the bank did not have policies to prevent conflicts of interest as required by regulation, a conclusion that might have caused a downgrade of the Wall Street bank's regulatory rating.
As a result of Segarra's findings, the New York Fed's Legal Compliance and Risk team voted to downgrade Goldman's annual rating pertaining to policies and procedures, according to the lawsuit filed in federal court in New York.
It is not clear whether the downgrade occurred, but according to the lawsuit, the threat of one startled Michael Silva, who oversees the New York Fed's relationship with Goldman, and Silva's deputy, Michael Koh. The two officials were concerned that a downgrade could cause clients to stop doing business with the Wall Street bank, the lawsuit said.
Silva and Koh are named as defendants in Segarra's lawsuit, as is her former supervisor, Johnathon J. Kim.
In a statement, New York Fed spokesman Jack Gutt said the regulator cannot speak about individual employees or about supervised institutions because the information is private.
"The New York Fed provides multiple venues and layers of recourse for its employees to freely express concerns about the institutions it supervises," said Gutt. "Such concerns are treated seriously and investigated appropriately with a high degree of independence. Personnel decisions at the New York Fed are based exclusively on individual job performance and are subject to thorough review. We categorically reject any suggestions to the contrary."
Goldman spokesman Michael DuVally said the bank does not have knowledge of internal Fed discussions or the matters raised by Segarra. He also pointed to a Business Standards Committee report that Goldman produced in January 2011, whose full implementation was announced in May of this year.
"Goldman Sachs has a comprehensive approach to addressing conflicts through firm wide and divisional policies and infrastructure," DuVally said.
Segarra was assigned to Goldman's legal and compliance divisions from October 2011 until May 2012, and looked into three controversial transactions related to Solyndra, Capmark and the merger of El Paso and Kinder Morgan . At that point, Kim, Silva and Koh fired her and had her escorted from the building by security guards after weeks of disputes and pressure to change her examination findings, the lawsuit said.
Segarra's lawyer, Linda Stengle, said in an interview that Goldman's committees and standards represented "a paper policy that didn't really have any weight." Stengle said that Goldman executives in charge of conflicts told Segarra and other Fed examiners that they did not have a firm wide conflicts policy and also gave inconsistent statements about the conflicts board's duties and findings.
"Bank examiners should be able to operate without fear of retaliation against the banks that they're examining," said Stengle. Instead, she said her client was "cornered" by supervisors who "tried to force her or persuade her very heavily to change her findings."
(Reporting by Lauren Tara LaCapra; Editing by Ken Wills)
'Pouchitis' after ulcerative colitis surgery linked to changes in gene expression
Public release date: 10-Oct-2013 [
| E-mail
| Share
]
Contact: Connie Hughes connie.hughes@wolterskluwer.com 646-674-6348 Wolters Kluwer Health
Study may provide insights into molecular events leading to inflammatory bowel disease
Philadelphia, Pa. (October 10, 2013) "Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
"Gene alterations in pouch inflammation and Crohn's disease overlap, suggesting that inflammatory bowel disease is a spectrum, rather than distinct diseases," according to the new research by Dr S. Ben Shachar and colleagues of Tel Aviv University, Israel. They believe the occurrence and progression of gene changes in previously normal intestine after UC surgery provides a useful model for studying the development of inflammatory bowel disease (IBD).
After UC Surgery, Gene Expression Changes in Patients with "Pouchitis"
The researchers analyzed gene expression changes in different groups of patients who had undergone "pouch" surgery for UC. In this procedure (restorative proctocolectomy), the entire large intestine is removed and a portion of small intestine (the ileum) is used to create a reservoir, or pouch, to restore bowel function.
Up to one-fourth of patients with UC need surgery because of unmanageable disease or complications. Surgery is effective, but has a substantial rate of complicationsespecially the development of inflammation in the newly created pouch, called pouchitis.
By definition, the small intestine is normal in UCin contrast to Crohn's disease (CD), which can affect any part of the gastrointestinal tract. The development of pouchitis after UC surgery thus provides an opportunity to study the "molecular events" associated with the development of IBD in previously normal tissue.
The researchers found no significant changes in gene expression in normal samples of ileum from patients with UC. In contrast, in patients who had undergone UC surgery, nearly 170 significant changes in gene expression were found in samples of tissue from the surgically created poucheven though the tissue still appeared normal.
In patients who had developed inflammation and other signs of pouchitis, the number of gene abnormalities increased to nearly 500. For those who progressed to develop "Crohn's-like" changes of the pouch tissue, the number of gene abnormalities increased to well over 1,000. Thus as the severity of pouch disease increased, so did the number of gene expression changes.
Overlapping Gene Alterations Linked to Increasing Inflammation
The types of gene expression changes overlapped significantly between groups. The alterations involved genes involved in a wide range of inflammatory processes, including responses to chemical stimuli, various metabolic and immune system processes, and pathways related to certain types of infections. The link to infectious processes might help to explain why IBD and pouchitis often respond well to treatment with antibiotics.
Since the number and extent of gene expression changes build up as pouchitis progresses, "molecular clustering" studies might be a useful part of clinical assessment for IBD, according to Dr Shachar and coauthors. The findings also suggest that pouchitisespecially Crohn's-like changesmay not be a separate different disease, "but rather the end of the IBD spectrum."
Perhaps most importantly, the development of pouchitis may provide a unique model for understanding how IBD develops and progresses. Dr Shachar and colleagues write, "We suggest that the pouch can serve for study of early IBD in humans, with the ultimate goals of tailoring intervention and devising strategies for prevention."
###
About Inflammatory Bowel Diseases
Inflammatory Bowel Diseases brings the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases, and investigators performing research in IBD and related fields. Each issue contains cutting-edge original basic science and clinical articles on diagnosis, treatment, and management of IBD from clinicians and researchers around the world. Coverage includes articles highlighting the unique and important issues in pediatric IBD, as well as articles pertaining to adult patients.
About the CCFA
The Crohn's & Colitis Foundation of America is a non-profit, volunteer-driven organization dedicated to finding the cures for Crohn's Disease and ulcerative colitis. It was founded in 1967 by Irwin M. and Suzanne Rosenthal, William D. and Shelby Modell, and Henry D. Janowitz, M.D. Since our founding over four decades ago, CCFA has remained at the forefront of research in Crohn's disease and ulcerative colitis. Today, we fund cutting-edge studies at major medical institutions, nurture investigators at the early stages of their careers, and finance underdeveloped areas of research.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health's customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language, Lexicomp, Lippincott Williams & Wilkins, Medicom, Medknow, Ovid, Pharmacy OneSource, ProVation Medical, and UpToDate.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of 3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
'Pouchitis' after ulcerative colitis surgery linked to changes in gene expression
Public release date: 10-Oct-2013 [
| E-mail
| Share
]
Contact: Connie Hughes connie.hughes@wolterskluwer.com 646-674-6348 Wolters Kluwer Health
Study may provide insights into molecular events leading to inflammatory bowel disease
Philadelphia, Pa. (October 10, 2013) "Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
"Gene alterations in pouch inflammation and Crohn's disease overlap, suggesting that inflammatory bowel disease is a spectrum, rather than distinct diseases," according to the new research by Dr S. Ben Shachar and colleagues of Tel Aviv University, Israel. They believe the occurrence and progression of gene changes in previously normal intestine after UC surgery provides a useful model for studying the development of inflammatory bowel disease (IBD).
After UC Surgery, Gene Expression Changes in Patients with "Pouchitis"
The researchers analyzed gene expression changes in different groups of patients who had undergone "pouch" surgery for UC. In this procedure (restorative proctocolectomy), the entire large intestine is removed and a portion of small intestine (the ileum) is used to create a reservoir, or pouch, to restore bowel function.
Up to one-fourth of patients with UC need surgery because of unmanageable disease or complications. Surgery is effective, but has a substantial rate of complicationsespecially the development of inflammation in the newly created pouch, called pouchitis.
By definition, the small intestine is normal in UCin contrast to Crohn's disease (CD), which can affect any part of the gastrointestinal tract. The development of pouchitis after UC surgery thus provides an opportunity to study the "molecular events" associated with the development of IBD in previously normal tissue.
The researchers found no significant changes in gene expression in normal samples of ileum from patients with UC. In contrast, in patients who had undergone UC surgery, nearly 170 significant changes in gene expression were found in samples of tissue from the surgically created poucheven though the tissue still appeared normal.
In patients who had developed inflammation and other signs of pouchitis, the number of gene abnormalities increased to nearly 500. For those who progressed to develop "Crohn's-like" changes of the pouch tissue, the number of gene abnormalities increased to well over 1,000. Thus as the severity of pouch disease increased, so did the number of gene expression changes.
Overlapping Gene Alterations Linked to Increasing Inflammation
The types of gene expression changes overlapped significantly between groups. The alterations involved genes involved in a wide range of inflammatory processes, including responses to chemical stimuli, various metabolic and immune system processes, and pathways related to certain types of infections. The link to infectious processes might help to explain why IBD and pouchitis often respond well to treatment with antibiotics.
Since the number and extent of gene expression changes build up as pouchitis progresses, "molecular clustering" studies might be a useful part of clinical assessment for IBD, according to Dr Shachar and coauthors. The findings also suggest that pouchitisespecially Crohn's-like changesmay not be a separate different disease, "but rather the end of the IBD spectrum."
Perhaps most importantly, the development of pouchitis may provide a unique model for understanding how IBD develops and progresses. Dr Shachar and colleagues write, "We suggest that the pouch can serve for study of early IBD in humans, with the ultimate goals of tailoring intervention and devising strategies for prevention."
###
About Inflammatory Bowel Diseases
Inflammatory Bowel Diseases brings the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases, and investigators performing research in IBD and related fields. Each issue contains cutting-edge original basic science and clinical articles on diagnosis, treatment, and management of IBD from clinicians and researchers around the world. Coverage includes articles highlighting the unique and important issues in pediatric IBD, as well as articles pertaining to adult patients.
About the CCFA
The Crohn's & Colitis Foundation of America is a non-profit, volunteer-driven organization dedicated to finding the cures for Crohn's Disease and ulcerative colitis. It was founded in 1967 by Irwin M. and Suzanne Rosenthal, William D. and Shelby Modell, and Henry D. Janowitz, M.D. Since our founding over four decades ago, CCFA has remained at the forefront of research in Crohn's disease and ulcerative colitis. Today, we fund cutting-edge studies at major medical institutions, nurture investigators at the early stages of their careers, and finance underdeveloped areas of research.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health's customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language, Lexicomp, Lippincott Williams & Wilkins, Medicom, Medknow, Ovid, Pharmacy OneSource, ProVation Medical, and UpToDate.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of 3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: 
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sS2gKBZsydQ8zTVXhCFV2Wkud1qyl6ZuRKek4cnRK02dGa6rM6bS7r_N1jCjcdnnMf-NEZenKjWkJz5frsSCn9eArikEJddV6xwZMM4XY=s0-d){kind=small}
Share